Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Oncology Research and Treatment · 2023
DOI: 10.1159/000531492 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Oncology Research and Treatment, 2023. Verfasst von Yuqin Ding und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
This multicenter, randomized, double-blind, placebo-controlled phase 2 trial compared the efficacy, and safety of adding pyrotinib to trastuzumab, docetaxel, and carboplatin versus placebo, trastuzumab, docetaxel, and carboplatin in Chinese patients with human epidermal receptor 2 (HER2)-positive early or locally advanced breast cancer (ClinicalTrials.gov identifier: NCT03756064).
Methods
Sixty-nine women with HER2-positive early (T1-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) were recruited from October 1, 2019, to June 1, 2021. Before surgery, patients received 6 cycles of orally pyrotinib (400 mg once per day), trastuzumab (8-mg/kg loading dose and 6-mg/kg maintenance doses), docetaxel (75 mg/m2), and carboplatin (AUC = 6 mg/mL·min) or orally placebo, trastuzumab, and docetaxel, and carboplatin every 3 weeks. The primary end point was independent review committee-assessed total pathologic complete response rate. The 2-sided Cochran-Mantel-Haenszel test, stratified by age, hormone receptor status, tumor stage, nodal status, cTNM stage, and Ki-67 level was used to compare rates between treatment groups.
Results
In total, 69 female patients were randomized (pyrotinib, 36; and placebo, 33; median age, 53 [31–69] years). In the intention-to-treat population, total pathologic complete response rates were 65.5% (19/29) in the pyrotinib group and 33.3% (10/30) in the placebo group (difference, 32.2%, p = 0.013). Diarrhea was been reported in 86.1% of patients (31/36) in the pyrotinib group as the most common adverse events (AEs) and 15.2% of patients (5/33) in the placebo group. But no grade 4 or 5 AEs were reported.
Conclusion
Treatment with pyrotinib, trastuzumab, docetaxel, and carboplatin resulted in a statistically significant improvement in the total pathologic complete response rate versus placebo, trastuzumab, docetaxel, and carboplatin for the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer in Chinese patients. Safety data were in line with the known pyrotinib safety profile and generally comparable between treatment groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
- Department of Breast Surgery, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China.
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Child psychology, Affiliated Mental Health Center and Hangzhou Seventh People's Hospital University School of Medicine, Hangzhou, China.
Zitieren
APA
Ding, Y., Mo, W., Xie, X., Wang, O., He, X., Zhao, S., Gu, X., Liang, C., Qin, C., Ding, K., Yang, H., & Ding, X. (2023). Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Oncology Research and Treatment. https://doi.org/10.1159/000531492
Vancouver
Ding Y, Mo W, Xie X, Wang O, He X, Zhao S, et al. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Oncology Research and Treatment. 2023. doi:10.1159/000531492
BibTeX
@article{Ding2023,
author = {Ding, Yuqin and Mo, Wenju and Xie, Xiaohong and Wang, Ouchen and He, Xiangming and Zhao, Shuai and Gu, Xidong and Liang, Chenlu and Qin, Chengdong and Ding, Kaijing and Yang, Hongjian and Ding, Xiaowen},
title = {Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial},
journal = {Oncology Research and Treatment},
year = {2023},
doi = {10.1159/000531492}
}
EUVIMED